The GRHL2/ZEB Feedback Loop—A Key Axis in the Regulation of EMT in Breast Cancer

More than 90% of cancer‐related deaths are caused by metastasis. Epithelial‐to‐Mesenchymal Transition (EMT) causes tumor cell dissemination while the reverse process, Mesenchymal‐to‐Epithelial Transition (MET) allows cancer cells to grow and establish a potentially deadly metastatic lesion. Recent evidence indicates that in addition to E and M, cells can adopt a stable hybrid Epithelial/Mesenchymal (E/M) state where they can move collectively leading to clusters of Circulating Tumor Cells—the “bad actors” of metastasis. EMT is postulated to occur in all four major histological breast cancer subtypes. Here, we identify a set of genes strongly correlated with CDH1 in 877 cancer cell lines, and differentially expressed genes in cell lines overexpressing ZEB1, SNAIL, and TWIST. GRHL2 and ESRP1 appear in both these sets and also correlate with CDH1 at the protein level in 40 breast cancer specimens. Next, we find that GRHL2 and CD24 expression coincide with an epithelial character in human mammary epithelial cells. Further, we show that high GRHL2 expression is highly correlated with worse relapse‐free survival in all four subtypes of breast cancer. Finally, we integrate CD24, GRHL2, and ESRP1 into a mathematical model of EMT regulation to validate the role of these players in EMT. Our data analysis and modeling results highlight the relationships among multiple crucial EMT/MET drivers including ZEB1, GRHL2, CD24, and ESRP1, particularly in basal‐like breast cancers, which are most similar to triple‐negative breast cancer (TNBC) and are considered the most dangerous subtype. J. Cell. Biochem. 118: 2559–2570, 2017. © 2017 Wiley Periodicals, Inc.

[1]  I Kimber,et al.  Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. , 2005, Journal of molecular endocrinology.

[2]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Moreno-Bueno,et al.  Correlation of Snail expression with histological grade and lymph node status in breast carcinomas , 2002, Oncogene.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  James E. Verdone,et al.  Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts , 2015, Medical Oncology.

[6]  M. Zöller.  CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells , 2015, Front. Immunol..

[7]  J. Mertz,et al.  Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway , 2009, BMC Cell Biology.

[8]  Eshel Ben-Jacob,et al.  Toward decoding the principles of cancer metastasis circuits. , 2014, Cancer research.

[9]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[10]  W. Driever,et al.  Zeb1 Regulates E-cadherin and Epcam (Epithelial Cell Adhesion Molecule) Expression to Control Cell Behavior in Early Zebrafish Development , 2013, The Journal of Biological Chemistry.

[11]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.

[12]  James E. Verdone,et al.  The Presence of Androgen Receptor Elements Regulates ZEB1 Expression in the Absence of Androgen Receptor , 2015, Journal of cellular biochemistry.

[13]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[14]  Wenxin Qin,et al.  Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling , 2016, Theranostics.

[15]  Parul Gupta,et al.  HER2 mediated de novo production of TGFβ leads to SNAIL driven epithelial‐to‐mesenchymal transition and metastasis of breast cancer , 2014, Molecular oncology.

[16]  E. Obermann,et al.  Nuclear Expression of Snail Is an Independent Negative Prognostic Factor in Human Breast Cancer , 2013, Disease markers.

[17]  K. Rajagopalan,et al.  Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer , 2013, Journal of cellular biochemistry.

[18]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Simone Brabletz,et al.  A self‐enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells , 2015, International journal of cancer.

[20]  D. Huylebroeck,et al.  Aptamers and Their Potential to Selectively Target Aspects of EGF, Wnt/β-Catenin and TGFβ–Smad Family Signaling , 2013, International journal of molecular sciences.

[21]  Prakash Kulkarni,et al.  Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins , 2016, Asian journal of andrology.

[22]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[23]  C. Meisinger,et al.  ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types , 2016, Nature Communications.

[24]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[25]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[26]  H. Levine,et al.  Clinical Medicine , 1997 .

[27]  A. Postigo,et al.  GLI2 cooperates with ZEB1 for transcriptional repression of CDH1 expression in human melanoma cells , 2013, Pigment cell & melanoma research.

[28]  B. Zhou,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[29]  Hiroshi Tanaka,et al.  Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell , 2012, Nature Communications.

[30]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[31]  S. Borstnar,et al.  Triple negative breast cancer – prognostic factors and survival , 2010, Radiology and oncology.

[32]  Shelley M Enger,et al.  Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[33]  Eshel Ben-Jacob,et al.  OVOL guides the epithelial-hybrid-mesenchymal transition , 2015, Oncotarget.

[34]  Larry Norton,et al.  Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.

[35]  A. Dragoi,et al.  FLASH protects ZEB1 from degradation and supports cancer cells' epithelial-to-mesenchymal transition , 2016, Oncogenesis.

[36]  Rongling Wu,et al.  Differential Gene Expression in Tamoxifen-Resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data , 2012, PloS one.

[37]  P. Zheng,et al.  CD24: from A to Z , 2010, Cellular and Molecular Immunology.

[38]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[39]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[40]  R. Kemler,et al.  The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. , 1989, The EMBO journal.

[41]  A. del Sol,et al.  Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival , 2015, PloS one.

[42]  Wen-He Huang,et al.  Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation , 2015, PloS one.

[43]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[44]  M. Mann,et al.  Super-SILAC mix for quantitative proteomics of human tumor tissue , 2010, Nature Methods.

[45]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[46]  M. Garcia-Blanco,et al.  Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2 , 2016, Molecular and Cellular Biology.

[47]  W. Hur,et al.  Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. , 2016, Biochemical and biophysical research communications.

[48]  S. Weiss,et al.  Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression , 2012, Proceedings of the National Academy of Sciences.

[49]  Ming Tan,et al.  GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification , 2016, Scientific Reports.

[50]  S. Mooney,et al.  Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells , 2011, Journal of cellular biochemistry.

[51]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[52]  J. Itou,et al.  Sal‐like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal‐like breast cancer , 2013, FEBS letters.

[53]  E. Ben-Jacob,et al.  Stability of the hybrid epithelial/mesenchymal phenotype , 2016, Oncotarget.

[54]  K. Pienta,et al.  Niche Inheritance: A Cooperative Pathway to Enhance Cancer Cell Fitness Through Ecosystem Engineering , 2014, Journal of cellular biochemistry.

[55]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[56]  M. K. Magnússon,et al.  HER2 induced EMT and tumorigenicity in breast epithelial progenitor cells is inhibited by coexpression of EGFR , 2015, Oncogene.

[57]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[58]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[60]  Udo Schumacher,et al.  Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer* , 2013, The Journal of Biological Chemistry.

[61]  Y. Luqmani,et al.  Estrogen Receptor Silencing Induces Epithelial to Mesenchymal Transition in Human Breast Cancer Cells , 2011, PloS one.

[62]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[63]  E. López-Bonet,et al.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) , 2012, Cell cycle.

[64]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[65]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[66]  R. Vessella,et al.  The biology and clinical implications of prostate cancer dormancy and metastasis , 2015, Journal of Molecular Medicine.

[67]  Hong Jiang,et al.  Grhl2 Determines the Epithelial Phenotype of Breast Cancers and Promotes Tumor Progression , 2012, PloS one.

[68]  Erik W Thompson,et al.  Epithelial to mesenchymal transition and breast cancer , 2009, Breast Cancer Research.

[69]  H. Ford,et al.  Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. , 2013, Cancer research.

[70]  M. Wicha,et al.  Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options , 2015, Scientific Reports.

[71]  B. Cieply,et al.  Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. , 2012, Cancer research.

[72]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Eshel Ben-Jacob,et al.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis , 2015, Front. Oncol..

[74]  J. Tagne,et al.  The Transcription Factors Grainyhead-like 2 and NK2-Homeobox 1 Form a Regulatory Loop That Coordinates Lung Epithelial Cell Morphogenesis and Differentiation* , 2012, The Journal of Biological Chemistry.

[75]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[76]  Deyu Li,et al.  YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. , 2016, Molecular medicine reports.

[77]  Eshel Ben-Jacob,et al.  MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination , 2013, Proceedings of the National Academy of Sciences.